Related Experiment Video
Updated: Mar 12, 2026
Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones
Published on: November 30, 2016
Local and transient gene expression primes the liver to resist cancer metastasis
Tyler J Goodwin1, Yingqiu Zhou1, Sara N Musetti1
1Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Abstract:
The liver is the primary site of metastasis for gastrointestinal cancers and is a location highly susceptible to the establishment of metastasis in numerous other primary cancers, including breast, lung, and pancreatic cancers. The current standard of care typically consists of primary tumor resection and systemic administration of potent but toxic chemotherapeutics, yielding a minimal improvement in the median survival rate. CXCL12, a chemokine, is a key factor for activating the migration/survival pathways of CXCR4+ cancer cells and for recruiting immunosuppressive cells to areas of inflammation. Therefore, reducing CXCL12 concentrations within the liver has the potential to decrease tumor and immunosuppressive cell activation/migration within the liver. However, because of off-target toxicities associated with systemic administration of anti-CXCL12 therapies, transient and liver-specific expression of a CXCL12 trap is necessary. To address this challenge, we developed a lipid calcium phosphate nanoparticle optimized for delivering plasmid DNA, encoding an engineered CXCL12 protein trap, to the nucleus of liver hepatocytes. This pCXCL12-trap formulation yielded transient (4 days) liver-specific expression, which greatly decreased the occurrence of liver metastasis in two aggressive liver metastasis models, including colorectal [CT-26(FL3)] and breast (4T1) cancers. Subsequent studies in an aggressive human colorectal liver metastasis model (HT-29) decreased the establishment of liver metastasis more effectively than did systemic administration of the CXCL12 protein trap and to a level comparable to a high-dose regimen of a potent CXCR4 antagonist (AMD3100).
Insights
A novel nanoparticle delivery system effectively targets the liver, reducing metastasis in colorectal and breast cancers by transiently trapping CXCL12. This approach offers a promising alternative to systemic therapies for liver metastasis.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- The liver is a common site for metastasis from various cancers, including gastrointestinal, breast, and lung.
- Current treatments for liver metastasis, such as surgery and chemotherapy, offer limited survival benefits and significant toxicity.
- The chemokine CXCL12 and its receptor CXCR4 play critical roles in cancer cell migration, survival, and immune suppression within the liver microenvironment.
Purpose of the Study:
- To develop a liver-specific, transient gene delivery system for a CXCL12 trap to reduce liver metastasis.
- To evaluate the efficacy of this targeted delivery system in preclinical models of aggressive liver metastasis.
Main Methods:
- Engineered a lipid calcium phosphate nanoparticle formulation for plasmid DNA delivery encoding a CXCL12 trap.
- Administered the nanoparticle formulation to mice, achieving transient (4-day) liver-specific expression of the CXCL12 trap in hepatocytes.
- Assessed the impact on liver metastasis in aggressive colorectal (CT-26, HT-29) and breast (4T1) cancer models.
Main Results:
- The liver-specific CXCL12 trap significantly reduced liver metastasis in both colorectal and breast cancer models.
- In a human colorectal liver metastasis model (HT-29), the nanoparticle formulation outperformed systemic CXCL12 trap administration.
- The efficacy of the targeted approach was comparable to a high dose of a CXCR4 antagonist (AMD3100).
Conclusions:
- Transient, liver-specific expression of a CXCL12 trap via nanoparticle delivery is a viable strategy to combat liver metastasis.
- This targeted nanomedicine approach shows potential for improved efficacy and reduced toxicity compared to systemic treatments.
- Further development could lead to novel therapeutic options for patients with liver metastatic disease.
Related Concept Videos
01:58Cell Specific Gene Expression
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:24Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:39lncRNA - Long Non-coding RNAs
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...